The immunology of parasite infections in immunocompromised hosts

Parasite Immunology

Volumn 28, Issue 11, 2006, Pages 549-565

  Evering, T ^a   Weiss, L M ^a  

^a ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

Author keywords

Cancer; Chemotherapy; HTLV 1; Immunocompromised; Steriods; Transplantation

Indexed keywords

ANTIBODY; CD1 ANTIGEN; CD59 ANTIGEN; COLONY STIMULATING FACTOR 1; CORTICOSTEROID; CYTOKINE; GAMMA INTERFERON; GAMMA INTERFERON RECEPTOR; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; IMMUNOGLOBULIN A; IMMUNOGLOBULIN E; IMMUNOGLOBULIN G; IMMUNOGLOBULIN G1; IMMUNOGLOBULIN M; IMMUNOSUPPRESSIVE AGENT; INFLIXIMAB; INITIATION FACTOR 4A; INTERLEUKIN 10; INTERLEUKIN 12; INTERLEUKIN 15; INTERLEUKIN 1BETA; INTERLEUKIN 2; INTERLEUKIN 3; INTERLEUKIN 4; INTERLEUKIN 5; INTERLEUKIN 6; RECOMBINANT INTERLEUKIN 12; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR ALPHA; UNINDEXED DRUG;

AMEBIASIS; BABESIA; BABESIOSIS; CRYPTOSPORIDIOSIS; CRYPTOSPORIDIUM; CYCLOSPORA; DISEASE SEVERITY; ENTAMOEBA HISTOLYTICA; GIARDIA; GIARDIASIS; HOST PARASITE INTERACTION; HUMAN; IMMUNE DEFICIENCY; IMMUNOSUPPRESSIVE TREATMENT; LEISHMANIA; LEISHMANIASIS; MALIGNANT NEOPLASTIC DISEASE; MENINGOENCEPHALITIS; MICROSPORIDA; MICROSPORIDIOSIS; NEMATODIASIS; PARASITOSIS; PLASMODIUM; PNEUMOCYSTIS JIROVECI; PRIORITY JOURNAL; PROTOZOAL INFECTION; REVIEW; STRONGYLOIDES STERCORALIS; STRONGYLOIDIASIS; SURVIVAL; TOXOPLASMA GONDII; TOXOPLASMOSIS; TRYPANOSOMA CRUZI; TRYPANOSOMIASIS;

ACQUIRED IMMUNODEFICIENCY SYNDROME; ANIMALS; HUMANS; IMMUNOCOMPROMISED HOST; PARASITIC DISEASES;

HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN T-LYMPHOTROPIC VIRUS 1;

EID: 33750082344     PISSN: 01419838     EISSN: 13653024     Source Type: Journal    
DOI: 10.1111/j.1365-3024.2006.00886.x     Document Type: Review

References (233)

1. Genta RM. Global prevalence of strongyloidiasis: critical review with epidemiologic insights into the prevention of disseminated disease. Rev Infect Dis 1989; 11 (5): 755-767.
2. Huchton P, Horn R. Strongyloidiasis. J Pediatr 1959; 55: 602-608.
3. Grove DI. Strongyloidiasis in Allied ex-prisoners of war in South-east Asia. Br Med J 1980; 280 (6214): 598-601.
4. Milder JE, Walzer PD, Kilgore G, Rutherford I & Klein M. Clinical features of Strongyloides stercoralis infection in an endemic area of the United States. Gastroenterology 1981; 80 (6): 1481-1488.
5. Scowden EB, Schaffner W & Stone WJ. Overwhelming strongyloidiasis: an unappreciated opportunistic infection. Medicine (Baltimore) 1978; 57 (6): 527-544.
6. Armstrong D & Paredes J. Strongyloidiasis; in Shalamer J, Pizzo P, Parrillo J, Masur H (eds): Respiratory Disease in the Immunocompromised Host. Philadelphia, Lippincott, 1991.
7. Igra-Siegman Y, Kapila R, Sen P, Kaminski ZC & Louria DB. Syndrome of hyperinfection with Strongyloides stercoralis. Rev Infect Dis 1981; 3 (3): 397-407.
8. Longworth D & Weller P. Hyperinfection Syndrome with Strongyloidiasis. New York, McGraw-Hill, 1986.
9. Rivera E, Maldonado N, Velez-Garcia E, Grillo AJ & Malaret G. Hyperinfection syndrome with Strongyloides stercoralis. Ann Intern Med 1970; 72 (2): 199-204.
10. Fagundas LA, Busato O & Brentano L. Strongyloidiasis: fatal complication of renal transplantation. Lancet 1971; 2 (7721): 439-440.
11. Genta RM, Douce RW & Walzer PD. Diagnostic implications of parasite-specific immune responses in immunocompromised patients with strongyloidiasis. J Clin Microbiol 1986; 23 (6): 1099-1103.
12. Abdul-Fattah MM, Nasr ME, Yousef SM, Ibraheem MI, Abdul-Wahhab SE & Soliman HM. Efficacy of ELISA in diagnosis of strongyloidiasis among the immune-compromised patients. J Egypt Soc Parasitol 1995; 25 (2): 491-498.
13. Genta RM, Frei DF & Linke MJ. Demonstration and partial characterization of parasite-specific immunoglobulin A responses in human strongyloidiasis. J Clin Microbiol 1987; 25 (8): 1505-1510.
14. Nakada K, Kohakura M, Komoda H & Hinuma Y. High incidence of HTLV antibody in carriers of Strongyloides stercoralis. Lancet 1984; 1 (8377): 633.
15. Neva FA, Filho JO, Gam AA et al. Interferon-γ and interleukin-4 responses in relation to serum IgE levels in persons infected with human T lymphotropic virus type I and Strongyloides stercoralis. J Infect Dis 1998; 178 (6): 1856-1859.
16. Robinson RD, Lindo JF, Neva FA et al. Immunoepidemiologic studies of Strongyloides stercoralis and human T lymphotropic virus type I infections in Jamaica. J Infect Dis 1994; 169 (3): 692-696.
17. Carvalho EM & Da Fonseca Porto A. Epidemiological and clinical interaction between HTLV-1 and Strongyloides stercoralis. Parasite Immunol 2004; 26 (11-12): 487-497.
18. Newton RC, Limpuangthip P, Greenberg S, Gam A & Neva FA. Strongyloides stercoralis hyperinfection in a carrier of HTLV-I virus with evidence of selective immunosuppression. Am J Med 1992; 92 (2): 202-208.
19. Feldman HA. Toxoplasmosis: an overview. Bull N Y Acad Med 1974; 50 (2): 110-127.
20. Ruskin J & Remington JS. Toxoplasmosis in the compromised host. Ann Intern Med 1976; 84 (2): 193-199.
21. Stinson EB, Bieber CP, Griepp RB, Clark DA, Shumway NE & Remington JS. Infectious complications after cardiac transplantation in man. Ann Intern Med 1971; 74 (1): 22-36.
22. Leak D & Meghji M. Toxoplasmic infection in cardiac disease. Am J Cardiol 1979; 43 (4): 841-849.
23. Denkers EY & Gazzinelli RT. Regulation and function of T-cell-mediated immunity during Toxoplasma gondii infection. Clin Microbiol Rev 1998; 11 (4): 569-588.
24. Yap GS & Sher A. Cell-mediated immunity to Toxoplasma gondii: initiation, regulation and effector function. Immunobiology 1999; 201 (2): 240-247.
25. Montoya JG, Liesenfeld O. Toxoplasmosis. Lancet 2004; 363 (9425): 1965-1976.
26. Hirsch R, Burke BA & Kersey JH. Toxoplasmosis in bone marrow transplant recipients. J Pediatr 1984; 105 (3): 426-428.
27. Jehn U, Fink M, Gundlach P et al. Lethal cardiac and cerebral toxoplasmosis in a patient with acute myeloid leukemia after successful allogeneic bone marrow transplantation. Transplantation 1984; 38 (4): 430-433.
28. D'Ercole C, Boubli L, Franck J et al. Recurrent congenital toxoplasmosis in a woman with lupus erythematosus. Prenat Diagn 1995; 15 (12): 1171-1175.
29. Welch PC, Masur H, Jones TC & Remington JS. Serologic diagnosis of acute lymphadenopathic toxoplasmosis. J Infect Dis 1980; 142 (2): 256-264.
30. Young JD & McGwire BS. Infliximab and reactivation of cerebral toxoplasmosis. N Engl J Med 2005; 353 (14): 1530-1531; discussion 1530-1.
31. McLeod R, Mack DG, Boyer K et al. Phenotypes and functions of lymphocytes in congenital toxoplasmosis. J Lab Clin Med 1990; 116 (5): 623-635.
32. Gazzinelli RT, Hakim FT, Hieny S, Shearer GM & Sher A. Synergistic role of CD4+ and CD8+ T lymphocytes in IFN-γ production and protective immunity induced by an attenuated Toxoplasma gondii vaccine. J Immunol 1991; 146 (1): 286-292.
33. Wilson EH & Hunter CA. The role of astrocytes in the immunopathogenesis of toxoplasmic encephalitis. Int J Parasitol 2004; 34 (5): 543-548.
34. Gazzinelli RT, Eltoum I, Wynn TA & Sher A. Acute cerebral toxoplasmosis is induced by in vivo neutralization of TNF-α and correlates with the down-regulated expression of inducible nitric oxide synthase and other markers of macrophage activation. J Immunol 1993; 151 (7): 3672-3681.
35. St Georgiev V & Albright JF. Cytokines and their role as growth factors and in regulation of immune responses. Ann N Y Acad Sci 1993; 685: 584-602.
36. Kasper LH & Boothroyd JC. T. gondii and toxoplasmosis; in: Warren KS, Agabian N (eds): Immunology and Molecular Biology of Parasitic Infections, 3rd edn. Cambridge: Blackwell Scientific, 1993.
37. Cherwinski HM, Schumacher JH, Brown KD & Mosmann TR. Two types of mouse helper T cell clone. III. Further differences in lymphokine synthesis between Th1 and Th2 clones revealed by RNA hybridization, functionally monospecific bioassays, and monoclonal antibodies. J Exp Med 1987; 166 (5): 1229-1244.
38. Scharton-Kersten T, Caspar P, Sher A & Denkers EY. Toxoplasma gondii: evidence for interleukin-12-dependent and-independent pathways of interferon-γ production induced by an attenuated parasite strain. Exp Parasitol 1996; 84 (2): 102-114.
39. Gazzinelli RT, Amichay D, Sharton-Kersten T, Grunwald E, Farber JM & Sher A. Role of macrophage-derived cytokines in the induction and regulation of cell-mediated immunity to Toxoplasma gondii. Curr Top Microbiol Immunol 1996; 219: 127-139.
40. Scharton-Kersten TM, Wynn TA, Denkers EY et al. In the absence of endogenous IFN-γ, mice develop unimpaired IL-12 responses to Toxoplasma gondii while failing to control acute infection. J Immunol 1996; 157 (9): 4045-4054.
41. Shirahata T, Yamashita T, Ohta C, Goto H & Nakane A. CD8+ T lymphocytes are the major cell population involved in the early gamma interferon response and resistance to acute primary Toxoplasma gondii infection in mice. Microbiol Immunol 1994; 38 (10): 789-796.
42. Deckert-Schluter M, Rang A, Weiner D et al. Interferon-γ receptor-deficiency renders mice highly susceptible to toxoplasmosis by decreased macrophage activation. Lab Invest 1996; 75 (6): 827-841.
43. Kasper LH, Matsuura T, Fonseka S, Arruda J, Channon JY & Khan IA. Induction of gammadelta T cells during acute murine infection with Toxoplasma gondii. J Immunol 1996; 157 (12): 5521-5527.
44. Nagasawa H, Oka M, Maeda K et al. Induction of heat shock protein closely correlates with protection against Toxoplasma gondii infection. Proc Natl Acad Sci USA 1992; 89 (7): 3155-3158.
45. Sharma SD, Hofflin JM & Remington JS. In vivo recombinant interleukin 2 administration enhances survival against a lethal challenge with Toxoplasma gondii. J Immunol 1985; 135 (6): 4160-4163.
46. Hefeneider SH, Conlon PJ, Henney CS & Gillis S. In vivo interleukin 2 administration augments the generation of alloreactive cytolytic T lymphocytes and resident natural killer cells. J Immunol 1983; 130 (1): 222-227.
47. Doherty TM, Seder RA & Sher A. Induction and regulation of IL-15 expression in murine macrophages. J Immunol 1996; 156 (2): 735-741.
48. Grabstein KH, Eisenman J, Shanebeck K et al. Cloning of a T cell growth factor that interacts with the beta chain of the interleukin-2 receptor. Science 1994; 264 (5161): 965-968.
49. Nishimura H, Hiromatsu K, Kobayashi N et al. IL-15 is a novel growth factor for murine gamma delta T cells induced by Salmonella infection. J Immunol 1996; 156 (2): 663-669.
50. Khan IA & Kasper LH. IL-15 augments CD8+ T cell-mediated immunity against Toxoplasma gondii infection in mice. J Immunol 1996; 157: 2103-2108.
51. Khan IA, Moretto M, Wei XQ, Williams M, Schwartzman JD & Liew FY. Treatment with soluble interleukin-15Rα exacerbates intracellular parasitic infection by blocking the development of memory CD8+ T cell response. J Exp Med 2002; 195 (11): 1463-1470.
52. Lieberman LA, Villegas EN & Hunter CA. Interleukin-15-deficient mice develop protective immunity to Toxoplasma gondii. Infect Immun 2004; 72 (11): 6729-6732.
53. Welch PA, Namen AE, Goodwin RG, Armitage R & Cooper MD. Human IL-7: a novel T cell growth factor. J Immunol 1989; 143 (11): 3562-3567.
54. Alderson MR, Sassenfeld HM & Widmer MB. Interleukin 7 enhances cytolytic T lymphocyte generation and induces lymphokine-activated killer cells from human peripheral blood. J Exp Med 1990; 172 (2): 577-587.
55. Swain SL, Weinberg AD, English M & Huston G. IL-4 directs the development of Th2-like helper effectors. J Immunol 1990; 145 (11): 3796-3806.
56. Nickdel MB, Lyons RE, Roberts F et al. Intestinal pathology during acute toxoplasmosis is IL-4 dependent and unrelated to parasite burden. Parasite Immunol 2004; 26 (2): 75-82.
57. Gazzinelli RT, Wysocka M, Hieny S et al. In the absence of endogenous IL-10, mice acutely infected with Toxoplasma gondii succumb to a lethal immune response dependent on CD4+ T cells and accompanied by overproduction of IL-12, IFN-γ and TNF-α. J Immunol 1996; 157 (2): 798-805.
58. McLeod R & Remington JS. Studies on the specificity of killing of intracellular pathogens by macrophages. Cell Immunol 1977; 34 (1): 156-174.
59. North RJ. The concept of the activated macrophage. J Immunol 1978; 121 (3): 806-809.
60. Babior BM. Oxygen-dependent microbial killing by phagocytes (first of two parts). N Engl J Med 1978; 298 (12): 659-668.
61. Nathan CF & Root RK. Hydrogen peroxide release from mouse peritoneal macrophages: dependence on sequential activation and triggering. J Exp Med 1977; 146 (6): 1648-1662.
62. Locksley RM & Klebanoff SJ. Oxygen-dependent microbicidal systems of phagocytes and host defense against intracellular protozoa. J Cell Biochem 1983; 22 (3): 173-185.
63. Nathan CF, Murray HW, Wiebe ME & Rubin BY. Identification of interferon-γ as the lymphokine that activates human macrophage oxidative metabolism and antimicrobial activity. J Exp Med 1983; 158 (3): 670-689.
64. Darcy F, Deslee D, Santoro F et al. Induction of a protective antibody-dependent response against toxoplasmosis by in vitro excreted/secreted antigens from tachyzoites of Toxoplasma gondii. Parasite Immunol 1988; 10 (5): 553-567.
65. Gross U, Roos T, Appoldt D & Heesemann J. Improved serological diagnosis of Toxoplasma gondii infection by detection of immunoglobulin A (IgA) and IgM antibodies against P30 by using the immunoblot technique. J Clin Microbiol 1992; 30 (6): 1436-1441.
66. Kedzierski L, Montgomery J, Bullen D et al. A leucine-rich repeat motif of Leishmania parasite surface antigen 2 binds to macrophages through the complement receptor 3. J Immunol 2004; 172 (8): 4902-4906.
67. Ma DD, Concannon AJ & Hayes J. Fatal leishmaniasis in renal-transport patient. Lancet 1979; 2 (8137): 311-312.
68. Dowlati Y. Cutaneous leishmaniasis: clinical aspect. Clin Dermatol 1996; 14 (5): 425-431.
69. Aliaga L, Cobo F, Mediavilla JD et al. Localized mucosal leishmaniasis due to Leishmania (Leishmania) infantum: clinical and microbiologic findings in 31 patients. Medicine (Baltimore) 2003; 82 (3): 147-158.
70. Manson-Bahr PE. Leishmaniasis. Int Rev Trop Med 1971; 4: 123-140.
71. Aebischer T, Moody SF & Handman E. Persistence of virulent Leishmania major in murine cutaneous leishmaniasis: a possible hazard for the host. Infect Immun 1993; 61 (1): 220-226.
72. Fernandez-Guerrero ML, Aguado JM, Buzon L et al. Visceral leishmaniasis in immunocompromised hosts. Am J Med 1987; 83 (6): 1098-1102.
73. Badaro R, Carvalho EM, Rocha H, Queiroz AC & Jones TC. Leishmania donovani: an opportunistic microbe associated with progressive disease in three immunocompromised patients. Lancet 1986; 1 (8482): 647-649.
74. Aguado JM, Gomez Berne J, Figuera A, de Villalobos E, Fernandez-Guerrero ML & Sanchez Fayos J. Visceral leishmaniasis (kala-azar) complicating acute leukaemia. J Infect 1983; 7 (3): 272-274.
75. Murray HW, Oca MJ, Granger AM & Schreiber RD. Requirement for T cells and effect of lymphokines in successful chemotherapy for an intracellular infection. Experimental visceral leishmaniasis. J Clin Invest 1989; 83 (4): 1253-1257.
76. Reed SG & Scott P. T-cell and cytokine responses in leishmaniasis. Curr Opin Immunol 1993; 5 (4): 524-531.
77. Abrahamsen MS, Lancto CA, Walcheck B, Layton W & Jutila MA. Localization of alpha/beta and gamma/delta T lymphocytes in Cryptosporidium parvum-infected tissues in naive and immune calves. Infect Immun 1997; 65 (6): 2428-2433.
78. Woelbing F, Kostka SL, Moelle K et al. Uptake of Leishmania major by dendritic cells is mediated by Fcγ receptors and facilitates acquisition of protective immunity. J Exp Med 2006; 203 (1): 177-188.
79. Pearson RD, Wheeler DA, Harrison LH & Kay HD. The immunobiology of leishmaniasis. Rev Infect Dis 1983; 5 (5): 907-927.
80. Murray HW, Flanders KC, Donaldson DD et al. Antagonizing deactivating cytokines to enhance host defense and chemotherapy in experimental visceral leishmaniasis. Infect Immun 2005; 73 (7): 3903-3911.
81. Weiser WY, Van Niel A, Clark SC, David JR & Remold HG. Recombinant human granulocyte/macrophage colony-stimulating factor activates intracellular killing of Leishmania donovani by human monocyte-derived macrophages. J Exp Med 1987; 166 (5): 1436-1446.
82. Carvalho EM, Teixeira RS & Johnson WD Jr. Cell-mediated immunity in American visceral leishmaniasis: reversible immunosuppression during acute infection. Infect Immun 1981; 33 (2): 498-500.
83. Skeiky YA, Guderian JA, Benson DR et al. A recombinant Leishmania antigen that stimulates human peripheral blood mononuclear cells to express a Th1-type cytokine profile and to produce interleukin 12. J Exp Med 1995; 181 (4): 1527-1537.
84. Amprey JL, Im JS, Turco SJ et al. A subset of liver NK T cells is activated during Leishmania donovani infection by CD1d-bound lipophosphoglycan. J Exp Med 2004; 200 (7): 895-904.
85. Amprey JL, Spath GF & Porcelli SA. Inhibition of CD1 expression in human dendritic cells during intracellular infection with Leishmania donovani. Infect Immun 2004; 72 (1): 589-592.
86. Kohl S, Pickering LK, Frankel LS & Yaeger RG. Reactivation of Chagas' disease during therapy of acute lymphocytic leukemia. Cancer 1982; 50 (5): 827-828.
87. Rivero I, Moravenik M, Morales J, Gomez M & de Rosas JM. Letter: Chagas's disease - another hazard in acute leukemia. N Engl J Med 1974; 290 (5): 285.
88. Ferreira MS & Borges AS. Some aspects of protozoan infections in immunocompromised patients - a review. Mem Inst Oswaldo Cruz 2002; 97 (4): 443-457.
89. Grant IH, Gold JW, Wittner M et al. Transfusion-associated acute Chagas disease acquired in the United States. Ann Intern Med 1989; 111 (10): 849-851.
90. Brener Z & Chiari E. The effects of some immunosuppressive agents in experimental chronic Chagas's disease. Trans R Soc Trop Med Hyg 1971; 65 (5): 629-636.
91. Andrade SG, Carneiro Filho A, de Souza AJ, de Lima ES & Andrade ZA. Influence of treatment with immunosuppressive drugs in mice chronically infected with Trypanosoma cruzi. Int J Exp Pathol 1997; 78 (6): 391-399.
92. Norris KA, Bradt B, Cooper NR & So M. Characterization of a Trypanosoma cruzi C3 binding protein with functional and genetic similarities to the human complement regulatory protein, decay-accelerating factor. J Immunol 1991; 147 (7): 2240-2247.
93. Tarleton RL & Scott DW. Initial induction of immunity, followed by suppression of responses to parasite antigens during Trypanosoma cruzi infection of mice. Parasite Immunol 1987; 9 (5): 579-589.
94. Rowland EC & Kuhn RE. Suppression of cellular responses in mice during Trypanosoma cruzi infections. Infect Immun 1978; 20 (2): 393-397.
95. Voltarelli JC, Donadi EA & Falcao RP. Immunosuppression in human acute Chagas disease. Trans R Soc Trop Med Hyg 1987; 81 (1): 169-170.
96. Harel-Bellan A, Joskowicz M, Fradelizi D & Eisen H. Modification of T-cell proliferation and interleukin 2 production in mice infected with Trypanosoma cruzi. Proc Natl Acad Sci USA 1983; 80 (11): 3466-3469.
97. Ouaissi A, Guevara-Espinoza A, Chabe F, Gomez-Corvera R & Taibi A. A novel and basic mechanism of immunosuppression in Chagas' disease: Trypanosoma cruzi releases in vitro and in vivo a protein which induces T cell unresponsiveness through specific interaction with cysteine and glutathione. Immunol Lett 1995; 48 (3): 221-224.
98. Graefe SE, Jacobs T, Wachter U, Broker BM & Fleischer B. CTLA-4 regulates the murine immune response to Trypanosoma cruzi infection. Parasite Immunol 2004; 26 (1): 19-28.
99. Kierszenbaum F. Chagas' disease and the autoimmunity hypothesis. Clin Microbiol Rev 1999; 12 (2): 210-223.
100. Homer MJ, Aguilar-Delfin I, Telford SR, 3rd, Krause PJ, Persing DH. Babesiosis. Clin Microbiol Rev 2000; 13 (3): 451-469.
101. Rosner F, Zarrabi MH, Benach JL & Habicht GS. Babesiosis in splenectomized adults. Review of 22 reported cases. Am J Med 1984; 76 (4): 696-701.
102. Zivkovic D, Speksnijder JE, Kuil H & Seinen W. Immunity to Babesia in mice. III. The effects of corticosteroids and antithymocyte serum on mice immune to Babesia rodhaini. Vet Immunol Immunopathol 1985; 9 (2): 131-142.
103. Saeki H & Ishii T. Effect of silica treatment on resistance to Babesia rodhaini infection in immunized mice. Vet Parasitol 1996; 61 (3-4): 201-210.
104. Meeusen E, Lloyd S & Soulsby EJ. Babesia microti in mice. Adoptive transfer of immunity with serum and cells. Aust J Exp Biol Med Sci 1984; 62 (5): 551-566.
105. Solomon JB, Forbes MG & Solomon GR. A possible role for natural killer cells in providing protection against Plasmodium berghei in early stages of infection. Immunol Lett 1985; 9 (6): 349-352.
106. James MA. Immunology of babesiosis; in Ristic M (ed.): Babesiosis of Domestic Animals and Man. Boca Raton, FL, CRC Press, 1988: 119-130.
107. Abdalla HS, Hussein HS & Kreier JP. Babesia rodhaini: passive protection of mice with immune serum. Tropenmed Parasitol 1978; 29 (3): 295-306.
108. Matsubara J, Koura M & Kamiyama T. Infection of immunodeficient mice with a mouse-adapted substrain of the gray strain of Babesia microti. J Parasitol 1993; 79 (5): 783-786.
109. Echaide IE, Hines SA, McElwain TF, Suarez CE, McGuire TC & Palmer GH. In vivo binding of immunoglobulin M to the surfaces of Babesia bigemina-infected erythrocytes. Infect Immun 1998; 66 (6): 2922-2927.
110. Jacobson RH, Parrodi F, Wright IG, Fitzgerald CJ & Dobson C. Babesia bovis: in vitro phagocytosis promoted by immune serum and by antibodies produced against protective antigens. Parasitol Res 1993; 79 (3): 221-226.
111. Ruebush MJ & Hanson WL. Transfer of immunity to Babesia microti of human origin using T lymphocytes in mice. Cell Immunol 1980; 52 (2): 255-265.
112. Igarashi I, Suzuki R, Waki S et al. Roles of CD4 (+) T cells and gamma interferon in protective immunity against Babesia microti infection in mice. Infect Immun 1999; 67 (8): 4143-4148.
113. Faubert G. Immune response to Giardia duodenalis. Clin Microbiol Rev 2000; 13 (1): 35-54, table of contents.
114. Ali SA & Hill DR. Giardia intestinalis. Curr Opin Infect Dis 2003; 16 (5): 453-460.
115. Eckmann L. Mucosal defences against Giardia. Parasite Immunol 2003; 25 (5): 259-270.
116. Stevens DP, Frank DM & Mahmoud AA. Thymus dependency of host resistance to Giardia muris infection: studies in nude mice. J Immunol 1978; 120 (2): 680-682.
117. Webster AD. Giardiasis and immunodeficiency diseases. Trans R Soc Trop Med Hyg 1980; 74 (4): 440-443.
118. Zhou P, Li E, Zhu N, Robertson J, Nash T & Singer SM. Role of interleukin-6 in the control of acute and chronic Giardia lamblia infections in mice. Infect Immun 2003; 71 (3): 1566-1568.
119. Tzipori S & Ward H. Cryptosporidiosis: biology, pathogenesis and disease. Microbes Infect 2002; 4 (10): 1047-1058.
120. Guerrant RL & Bobak DA. Bacterial and protozoal gastroenteritis. N Engl J Med 1991; 325 (5): 327-340.
121. Mead JR, Arrowood MJ, Sidwell RW & Healey MC. Chronic Cryptosporidium parvum infections in congenitally immunodeficient SCID and nude mice. J Infect Dis 1991; 163 (6): 1297-1304.
122. Soave R & Johnson WD Jr. Cryptosporidium and Isospora belli infections. J Infect Dis 1988; 157 (2): 225-229.
123. Lewthwaite P, Gill GV, Hart CA & Beeching NJ. Gastrointestinal parasites in the immunocompromised. Curr Opin Infect Dis 2005; 18 (5): 427-435.
124. Thea DM, Pereira ME, Kotler D, Sterling CR & Keusch GT. Identification and partial purification of a lectin on the surface of the sporozoite of Cryptosporidium parvum. J Parasitol 1992; 78 (5): 886-893.
125. Joe A, Hamer DH, Kelley MA et al. Role of a Gal/GalNAc-specific sporozoite surface lectin in Cryptosporidium parvum-host cell interaction. J Eukaryot Microbiol 1994; 41 (5): 44S.
126. Rehg JE, Hancock ML & Woodmansee DB. Characterization of a dexamethasone-treated rat model of cryptosporidial infection. J Infect Dis 1988; 158 (6): 1406-1407.
127. Martino P, Gentile G, Caprioli A et al. Hospital-acquired cryptosporidiosis in a bone marrow transplantation unit. J Infect Dis 1988; 158 (3): 647-648.
128. Urban JF Jr, Fayer R, Chen SJ, Gause WC, Gately MK & Finkelman FD. IL-12 protects immunocompetent and immunodeficient neonatal mice against infection with Cryptosporidium parvum. J Immunol 1996; 156 (1): 263-268.
129. McDonald V. Host cell-mediated responses to infection with Cryptosporidium. Parasite Immunol 2000; 22 (12): 597-604.
130. McDonald V, Robinson HA, Kelly JP & Bancroft GJ. Immunity to Cryptosporidium muris infection in mice is expressed through gut CD4+ intraepithelial lymphocytes. Infect Immun 1996; 64 (7): 2556-2562.
131. Waters WR & Harp JA. Cryptosporidium parvum infection in T-cell receptor (TCR)-α- and TCR-δ-deficient mice. Infect Immun 1996; 64 (5): 1854-1857.
132. Aguirre SA, Mason PH & Perryman LE. Susceptibility of major histocompatibility complex (MHC) class I- and MHC class II-deficient mice to Cryptosporidium parvum infection. Infect Immun 1994; 62 (2): 697-699.
133. Tilley M, McDonald V & Bancroft GJ. Resolution of cryptosporidial infection in mice correlates with parasite-specific lymphocyte proliferation associated with both Th1 and Th2 cytokine secretion. Parasite Immunol 1995; 17 (9): 459-464.
134. Enriquez FJ & Sterling CR. Role of CD4+ TH1- and TH2-cell-secreted cytokines in cryptosporidiosis. Folia Parasitol (Praha) 1993; 40 (4): 307-311.
135. Ungar BL, Soave R, Fayer R & Nash TE. Enzyme immunoassay detection of immunoglobulin M and G antibodies to Cryptosporidium in immunocompetent and immunocompromised persons. J Infect Dis 1986; 153 (3): 570-578.
136. Lasser KH, Lewin KJ & Ryning FW. Cryptosporidial enteritis in a patient with congenital hypogammaglobulinemia. Hum Pathol 1979; 10 (2): 234-240.
137. Riggs MW, Yount PA, Stone AL & Langer RC. Protective monoclonal antibodies define a distinct, conserved epitope on an apical complex exoantigen of Cryptosporidium parvum sporozoites. J Eukaryot Microbiol 1996; 43 (5): 74S-75S.
138. Langer RC & Riggs MW. Neutralizing monoclonal antibody protects against Cryptosporidium parvum infection by inhibiting sporozoite attachment and invasion. J Eukaryot Microbiol 1996; 43 (5): 76S-77S.
139. Bjorneby JM, Hunsaker BD, Riggs MW & Perryman LE. Monoclonal antibody immunotherapy in nude mice persistently infected with Cryptosporidium parvum. Infect Immun 1991; 59 (3): 1172-1176.
140. Perryman LE, Riggs MW, Mason PH & Fayer R. Kinetics of Cryptosporidium parvum sporozoite neutralization by monoclonal antibodies, immune bovine serum, and immune bovine colostrum. Infect Immun 1990; 58 (1): 257-259.
141. Flanigan T, Marshall R, Redman D, Kaetzel C & Ungar B. In vitro screening of therapeutic agents against Cryptosporidium: hyperimmune cow colostrum is highly inhibitory. J Protozool 1991; 38 (6): 225S-227S.
142. Fayer R, Perryman LE & Riggs MW. Hyperimmune bovine colostrum neutralizes Cryptosporidium sporozoites and protects mice against oocyst challenge. J Parasitol 1989; 75 (1): 151-153.
143. Brussow H, Hilpert H, Walther I, Sidoti J, Mietens C & Bachmann P. Bovine milk immunoglobulins for passive immunity to infantile rotavirus gastroenteritis. J Clin Microbiol 1987; 25 (6): 982-986.
144. Saxon A & Weinstein W. Oral administration of bovine colostrum anti-cryptosporidia antibody fails to alter the course of human cryptosporidiosis. J Parasitol 1987; 73 (2): 413-415.
145. Ungar BL, Ward DJ, Fayer R & Quinn CA. Cessation of Cryptosporidium-associated diarrhea in an acquired immunodeficiency syndrome patient after treatment with hyperimmune bovine colostrum. Gastroenterology 1990; 98 (2): 486-489.
146. Borowitz SM & Saulsbury FT. Treatment of chronic cryptosporidial infection with orally administered human serum immune globulin. J Pediatr 1991; 119 (4): 593-595.
147. Mansfield LS & Gajadhar AA. Cyclospora cayetanensis, a food- and waterborne coccidian parasite. Vet Parasitol 2004; 126 (1-2): 73-90.
148. Ortega YR, Sterling CR, Gilman RH, Cama VA & Diaz F. Cyclospora species - a new protozoan pathogen of humans. N Engl J Med 1993; 328 (18): 1308-1312.
149. Soave R & Johnson WD Jr. Cyclospora: conquest of an emerging pathogen. Lancet 1995; 345 (8951): 667-668.
150. Yazar S, Yalcln S & Sahin I. Human cyclosporiosis in Turkey. World J Gastroenterol 2004; 10 (12): 1844-1847.
151. Fryauff DJ, Krippner R, Prodjodipuro P et al. Cyclospora cayetanensis among expatriate and indigenous populations of West Java, Indonesia. Emerg Infect Dis 1999; 5 (4): 585-588.
152. Niu MT & Duma RJ. Meningitis due to protozoa and helminths. Infect Dis Clin North Am 1990; 4 (4): 809-841.
153. John DT. Primary amebic meningoencephalitis and the biology of Naegleria fowleri. Annu Rev Microbiol 1982; 36: 101-123.
154. Oh YH, Jeong SR, Kim JH et al. Cytopathic changes and pro-inflammatory cytokines induced by Naegleria fowleri trophozoites in rat microglial cells and protective effects of an anti-Nfa1 antibody. Parasite Immunol 2005; 27 (12): 453-459.
155. Stauffer W & Ravdin JI. Entamoeba histolytica: an update. Curr Opin Infect Dis 2003; 16 (5): 479-485.
156. el-Hennawy M & Abd-Rabbo H. Hazards of cortisone therapy in hepatic amoebiasis. J Trop Med Hyg 1978; 81 (4): 71-73.
157. Denis M & Chadee K. Immunopathology of Entamoeba histolytica infections. Parasitol Today 1988; 4 (9): 247-252.
158. Kretschmer RR. Immune phenomena in amebiasis. Surv Immunol Res 1984; 3 (1): 1-10.
159. Trissl D. Immunology of Entamoeba histolytica in human and animal hosts. Rev Infect Dis 1982; 4 (6): 1154-1184.
160. Reed SL, Curd JG, Gigli I, Gillin FD & Braude AI. Activation of complement by pathogenic and nonpathogenic Entamoeba histolytica. J Immunol 1986; 136 (6): 2265-2270.
161. Braga LL, Ninomiya H, McCoy JJ et al. Inhibition of the complement membrane attack complex by the galactose-specific adhesin of Entamoeba histolytica. Arch Med Res 1992; 23 (2): 133.
162. Reed SL, Ember JA, Herdman DS, DiScipio RG, Hugli TE & Gigli I. The extracellular neutral cysteine proteinase of Entamoeba histolytica degrades anaphylatoxins C3a and C5a. J Immunol 1995; 155 (1): 266-274.
163. Beving DE, Soong CJ & Ravdin JI. Oral immunization with a recombinant cysteine-rich section of the Entamoeba histolytica galactose-inhibitable lectin elicits an intestinal secretory immunoglobulin A response that has in vitro adherence inhibition activity. Infect Immun 1996; 64 (4): 1473-1476.
164. Haque R, Duggal P, Ali IM et al. Innate and acquired resistance to amebiasis in Bangladeshi children. J Infect Dis 2002; 186 (4): 547-552.
165. Petri WA Jr, Jackson TF, Gathiram V et al. Pathogenic and nonpathogenic strains of Entamoeba histolytica can be differentiated by monoclonal antibodies to the galactose-specific adherence lectin. Infect Immun 1990; 58 (6): 1802-1806.
166. Pillai DR, Wan PS, Yau YC, Ravdin JI & Kain KC. The cysteine-rich region of the Entamoeba histolytica adherence lectin (170-kilodalton subunit) is sufficient for high-affinity Gal/GalNAc-specific binding in vitro. Infect Immun 1999; 67 (8): 3836-3841.
167. Seydel KB, Li E, Zhang Z & Stanley SL Jr. Epithelial cell-initiated inflammation plays a crucial role in early tissue damage in amebic infection of human intestine. Gastroenterology 1998; 115 (6): 1446-1453.
168. Denis M & Chadee K. Cytokine activation of murine macrophages for in vitro killing of Entamoeba histolytica trophozoites. Infect Immun 1989; 57 (6): 1750-1756.
169. Denis M & Chadee K. Human neutrophils activated by interferon-gamma and tumour necrosis factor-alpha kill Entamoeba histolytica trophozoites in vitro. J Leukoc Biol 1989; 46 (3): 270-274.
170. Lipschik GY & Masur H. Pneumocystis carinii pneumonia (PCP). Prog Clin Parasitol 1991; 2: 27-71.
171. Thomas CF Jr & Limper AH. Pneumocystis pneumonia. N Engl J Med 2004; 350 (24): 2487-2498.
172. Stringer SL, Stringer JR, Blase MA, Walzer PD & Cushion MT. Pneumocystis carinii: sequence from ribosomal RNA implies a close relationship with fungi. Exp Parasitol 1989; 68 (4): 450-461.
173. Edman JC, Kovacs JA, Masur H, Santi DV, Elwood HJ & Sogin ML. Ribosomal RNA sequence shows Pneumocystis carinii to be a member of the fungi. Nature 1988; 334 (6182): 519-522.
174. Wyder MA, Rasch EM & Kaneshiro ES. Quantitation of absolute Pneumocystis carinii nuclear DNA content. Trophic and cystic forms isolated from infected rat lungs are haploid organisms. J Eukaryot Microbiol 1998; 45 (3): 233-239.
175. Afessa B, Green W, Chiao J & Frederick W. Pulmonary complications of HIV infection: autopsy findings. Chest 1998; 113 (5): 1225-1229.
176. Morris A, Beard CB & Huang L. Update on the epidemiology and transmission of Pneumocystis carinii. Microbes Infect 2002; 4 (1): 95-103.
177. Hughes WT. Current issues in the epidemiology, transmission, and reactivation of Pneumocystis carinii. Semin Respir Infect 1998; 13 (4): 283-288.
178. Brazinsky JH & Phillips JE. Pneumocystis pneumonia transmission between patients with lymphoma. JAMA 1969; 209 (10): 1527.
179. Hughes WT, Feldman S, Aur RJ, Verzosa MS, Hustu HO & Simone JV. Intensity of immunosuppressive therapy and the incidence of Pneumocystis carinii pneumonitis. Cancer 1975; 36 (6): 2004-2009.
180. Rubin RH & Young LS. Clinical Approach to Infection in the Compromised Host, 4th edn. New York, Kluwer Academic/Plenum, 2002.
181. Yale SH & Limper AH. Pneumocystis carinii pneumonia in patients without acquired immunodeficiency syndrome: associated illness and prior corticosteroid therapy. Mayo Clin Proc 1996; 71 (1): 5-13.
182. Sepkowitz KA. Opportunistic infections in patients with and patients without acquired immunodeficiency syndrome. Clin Infect Dis 2002; 34 (8): 1098-1107.
183. Leff RL & Case JP. Rheumatoid arthritis, methotrexate therapy, and Pneumocystis pneumonia. Ann Intern Med 1990; 112 (9): 716.
184. Perruquet JL, Harrington TM & Davis DE. Pneumocystis carinii pneumonia following methotrexate therapy for rheumatoid arthritis. Arthritis Rheum 1983; 26 (10): 1291-1292.
185. Wallis PJ, Ryatt KS & Constable TJ. Pneumocystis carinii pneumonia complicating low dose methotrexate treatment for psoriatic arthropathy. Ann Rheum Dis 1989; 48 (3): 247-249.
186. Hughes WT, Price RA, Sisko F et al. Protein-calorie malnutrition. A host determinant for Pneumocystis carinii infection. Am J Dis Child 1974; 128 (1): 44-52.
187. Walzer PD, Schnelle V, Armstrong D & Rosen PP. Nude mouse: a new experimental model for Pneumocystis carinii infection. Science 1977; 197 (4299): 177-179.
188. Kovacs JA, Hiemenz JW, Macher AM et al. Pneumocystis carinii pneumonia: a
189. Limper AH, Standing JE, Hoffman OA, Castro M & Neese LW. Vitronectin binds to Pneumocystis carinii and mediates organism attachment to cultured lung epithelial cells. Infect Immun 1993; 61 (10): 4302-4309.
190. Walzer PD. Attachment of microbes to host cells. Relevance of Pneumocystis carinii. Lab Invest 1986; 54 (6): 589-592.
191. O'Riordan DM, Standing JE, Kwon KY, Chang D, Crouch EC & Limper AH. Surfactant protein D interacts with Pneumocystis carinii and mediates organism adherence to alveolar macrophages. J Clin Invest 1995; 95 (6): 2699-2710.
192. Williams MD, Wright JR, March KL & Martin WJ, 2nd. Human surfactant protein A enhances attachment of Pneumocystis carinii to rat alveolar macrophages. Am J Respir Cell Mol Biol 1996; 14 (3): 232-238.
193. Yong SJ, Vuk-Pavlovic Z, Standing JE, Crouch EC & Limper AH. Surfactant protein D-mediated aggregation of Pneumocystis carinii impairs phagocytosis by alveolar macrophages. Infect Immun 2003; 71 (4): 1662-1671.
194. O'Riordan DM, Standing JE & Limper AH. Pneumocystis carinii glycoprotein A binds macrophage mannose receptors. Infect Immun 1995; 63 (3): 779-784.
195. Linke MJ, Cushion MT & Walzer PD. Properties of the major antigens of rat and human Pneumocystis carinii. Infect Immun 1989; 57 (5): 1547-1555.
196. Douglas CM. Fungal beta (1,3)-D-glucan synthesis. Med Mycol 2001; 39 (Suppl. 1): 55-66.
197. Vassallo R, Standing JE & Limper AH. Isolated Pneumocystis carinii cell wall glucan provokes lower respiratory tract inflammatory responses. J Immunol 2000; 164 (7): 3755-3763.
198. Benfield TL, Prento P, Junge J, Vestbo J & Lundgren JD. Alveolar damage in AIDS-related Pneumocystis carinii pneumonia. Chest 1997; 111 (5): 1193-1199.
199. Beck JM, Preston AM, Wagner JG et al. Interaction of rat Pneumocystis carinii and rat alveolar epithelial cells in vitro. Am J Physiol 1998; 275 (1 Part 1): L118-L125.
200. Limper AH, Offord KP, Smith TF & Martin WJ, 2nd. Pneumocystis carinii pneumonia. Differences in lung parasite number and inflammation in patients with and without AIDS. Am Rev Respir Dis 1989; 140 (5): 1204-1209.
201. Harmsen AG & Stankiewicz M. Requirement for CD4+ cells in resistance to Pneumocystis carinii pneumonia in mice. J Exp Med 1990; 172 (3): 937-945.
202. Shellito J, Suzara VV, Blumenfeld W, Beck JM, Steger HJ & Ermak TH. A new model of Pneumocystis carinii infection in mice selectively depleted of helper T lymphocytes. J Clin Invest 1990; 85 (5): 1686-1693.
203. Furuta T, Ueda K, Kyuwa S & Fujiwara K. Effect of T-cell transfer on Pneumocystis carinii infection in nude mice. Jpn J Exp Med 1984; 54 (2): 57-64.
204. Roths JB, Marshall JD, Allen RD, Carlson GA & Sidman CL. Spontaneous Pneumocystis carinii pneumonia in immunodeficient mutant scid mice. Natural history and pathobiology. Am J Pathol 1990; 136 (5): 1173-1186.
205. Beck JM & Harmsen AG. Lymphocytes in host defense against Pneumocystis carinii. Semin Respir Infect 1998; 13 (4): 330-338.
206. Phair J, Munoz A, Detels R, Kaslow R, Rinaldo C & Saah A. The risk of Pneumocystis carinii pneumonia among men infected with human immunodeficiency virus type 1. Multicenter AIDS Cohort Study Group. N Engl J Med 1990; 322 (3): 161-165.
207. + T cells. J Immunol 1999; 162 (5): 2890-2894.
208. Wright TW, Gigliotti F, Finkelstein JN, McBride JT, An CL & Harmsen AG. Immune-mediated inflammation directly impairs pulmonary function, contributing to the pathogenesis of Pneumocystis carinii pneumonia. J Clin Invest 1999; 104 (9): 1307-1317.
209. Wright TW, Pryhuber GS, Chess PR, Wang Z, Notter RH & Gigliotti F. TNF receptor signaling contributes to chemokine secretion, inflammation, and respiratory deficits during Pneumocystis pneumonia. J Immunol 2004; 172 (4): 2511-2521.
210. + T cells are effector cells against pneumocystis in mice. J Immunol 2004; 172 (2): 1132-1138.
211. Wright TW, Johnston CJ, Harmsen AG & Finkelstein JN. Chemokine gene expression during Pneumocystis carinii-driven pulmonary inflammation. Infect Immun 1999; 67 (7): 3452-3460.
212. Benfield TL, Vestbo J, Junge J, Nielsen TL, Jensen AB & Lundgren JD. Prognostic value of interleukin-8 in AIDS-associated Pneumocystis carinii pneumonia. Am J Respir Crit Care Med 1995; 151 (4): 1058-1062.
213. Swain SD, Wright TW, Degel PM, Gigliotti F & Harmsen AG. Neither neutrophils nor reactive oxygen species contribute to tissue damage during Pneumocystis pneumonia in mice. Infect Immun 2004; 72 (10): 5722-5732.
214. Koziel H, Eichbaum Q, Kruskal BA et al. Reduced binding and phagocytosis of Pneumocystis carinii by alveolar macrophages from persons infected with HIV-1 correlates with mannose receptor downregulation. J Clin Invest 1998; 102 (7): 1332-1344.
215. Vargas SL, Hughes WT, Santolaya ME et al. Search for primary infection by Pneumocystis carinii in a cohort of normal, healthy infants. Clin Infect Dis 2001; 32 (6): 855-861.
216. Lund FE, Schuer K, Hollifield M, Randall TD & Garvy BA. Clearance of Pneumocystis carinii in mice is dependent on B cells but not on P. carinii-specific antibody. J Immunol 2003; 171 (3): 1423-1430.
217. Weber R, Bryan RT, Schwartz DA & Owen RL. Human microsporidial infections. Clin Microbiol Rev 1994; 7 (4): 426-461.
218. Didier ES, Didier PJ, Friedberg DN et al. Isolation and characterization of a new human microsporidian, Encephalitozoon hellem (n. sp.), from three AIDS patients with keratoconjunctivitis. J Infect Dis 1991; 163 (3): 617-621.
219. Canning EU, Lorn I & Dykova I. The Microsporidia of Vertebrates. New York, Academic Press, 1986.
220. Cali A. General microsporidian features and recent findings on AIDS isolates. J Protozool 1991; 38 (6): 625-630.
221. Wittner M, Tanowitz HB & Weiss LM. Parasitic infections in AIDS patients. Cryptosporidiosis, isosporiasis, microsporidiosis, cyclosporiasis. Infect Dis Clin North Am 1993; 7 (3): 569-586.
222. Sandfort J, Hannemann A, Gelderblom H, Stark K, Owen RL & Ruf B. Enterocytozoon bieneusi infection in an immunocompetent patient who had acute diarrhea and who was not infected with the human immunodeficiency virus. Clin Infect Dis 1994; 19 (3): 514-516.
223. Shadduck JA & Greeley E. Microsporidia and human infections. Clin Microbiol Rev 1989; 2 (2): 158-165.
224. Bryan RT, Weber R & Microsporidia. Emerging pathogens in immunodeficient persons. Arch Pathol Lab Med 1993; 117 (12): 1243-1245.
225. Innes JR. Parasitic infections of the nervous system of animals. Ann N Y Acad Sci 1970; 174 (2): 1042-1047.
226. Schmidt EC & Shadduck JA. Murine encephalitozoonosis model for studying the host-parasite relationship of a chronic infection. Infect Immun 1983; 40 (3): 936-942.
227. Koudela B, Vitovec J, Kucerova Z, Ditrich O & Travnicek J. The severe combined immunodeficient mouse as a model for Encephalitozoon cuniculi microsporidiosis. Folia Parasitol (Praha) 1993; 40 (4): 279-286.
228. Khan IA & Moretto M. Role of gamma interferon in cellular immune response against murine Encephalitozoon cuniculi infection. Infect Immun 1999; 67 (4): 1887-1893.
229. Khan IA, Schwartzman JD, Kasper LH & Moretto M. CD8+ CTLs are essential for protective immunity against Encephalitozoon cuniculi infection. J Immunol 1999; 162 (10): 6086-6091.
230. Khan IA, Moretto M & Weiss LM. Immune response to Encephalitozoon cuniculi infection. Microbes Infect 2001; 3 (5): 401-405.
231. Didier ES, Varner PW, Didier PJ et al. Experimental microsporidiosis in immunocompetent and immunodeficient mice and monkeys. Folia Parasitol (Praha) 1994; 41 (1): 1-11.
232. Schmidt EC & Shadduck JA. Mechanisms of resistance to the intracellular protozoan Encephalitozoon cuniculi in mice. J Immunol 1984; 133 (5): 2712-2719.
233. Niederkorn JY & Shadduck JA. Role of antibody and complement in the control of Encephalitozoon cuniculi infections by rabbit macrophages. Infect Immun 1980; 27 (3): 995-1002.